Skip to main content

Table 2 Clinical features of mice receiving donor cells from MOG 35-55 -immunized, vehicle-treated or mepazine-treated mice

From: Pharmacological inhibition of MALT1 protease activity protects mice in a mouse model of multiple sclerosis

Donor cells Incidence Day of disease onset Mean maximal clinical score
Vehicle 100% (5/5) 21.0 ± 1.5 4.4 ± 0.3
Mepazine 60% (3/5) 17.7 ± 1.3 2.5 ± 0.7